These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 7949187)

  • 1. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.
    Wattel E; Preudhomme C; Hecquet B; Vanrumbeke M; Quesnel B; Dervite I; Morel P; Fenaux P
    Blood; 1994 Nov; 84(9):3148-57. PubMed ID: 7949187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
    Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
    Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.
    Preudhomme C; Dervite I; Wattel E; Vanrumbeke M; Flactif M; Lai JL; Hecquet B; Coppin MC; Nelken B; Gosselin B
    J Clin Oncol; 1995 Apr; 13(4):812-20. PubMed ID: 7707106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Fasan A; Haferlach C
    Leukemia; 2017 Mar; 31(3):705-711. PubMed ID: 27680515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
    Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
    Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia.
    Preudhomme C; Lubin R; Lepelley P; Vanrumbeke M; Fenaux P
    Leukemia; 1994 Sep; 8(9):1589-91. PubMed ID: 8090036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
    Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
    Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia.
    Mori N; Hidai H; Yokota J; Okada M; Motoji T; Oshimi K; Mizoguchi H
    Leuk Res; 1995 Nov; 19(11):869-75. PubMed ID: 8551805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis.
    Lepelley P; Soenen V; Preudhomme C; Merlat A; Cosson A; Fenaux P
    Leukemia; 1995 Apr; 9(4):726-30. PubMed ID: 7723410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
    Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
    Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS).
    Neubauer A; Brendel C; Vogel D; Schmidt CA; Heide I; Huhn D
    Ann Hematol; 1993 Nov; 67(5):223-6. PubMed ID: 8241345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.